Serguei Nabirotchkin
YOU?
Author Swipe
View article: Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis
Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis Open
There is currently no therapy impacting the course of amyotrophic lateral sclerosis (ALS). The only approved treatments are riluzole and edaravone, but their efficacy is modest and short‐lasting, highlighting the need for innovative therap…
View article: Author response for "Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis"
Author response for "Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis" Open
View article: Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats Open
Charcot–Marie–Tooth disease 1 A (CMT1A) is caused by an intrachromosomal duplication of the gene encoding for PMP22 leading to peripheral nerve dysmyelination, axonal loss, and progressive muscle weakness. No therapy is available. PXT3003 …
View article: Author response for "Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis"
Author response for "Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis" Open
View article: Author response for "Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats"
Author response for "Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats" Open
View article: Author response for "Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats"
Author response for "Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats" Open
View article: Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19
Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19 Open
More than 179,000 individuals have fallen ill of the Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus, which first emerged in China less than four months ago in December 2019. As of today, there exist no approved treatments ag…
View article: Next-generation drug repurposing using human genetics and network biology
Next-generation drug repurposing using human genetics and network biology Open
Drug repurposing has attracted increased attention, especially in the context of drug discovery rates that remain too low despite a recent wave of approvals for biological therapeutics (e.g. gene therapy). These new biological entities-bas…
View article: Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A)
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A) Open
The most common type of Charcot-Marie-Tooth disease is caused by a duplication of PMP22 leading to dysmyelination, axonal loss and progressive muscle weakness (CMT1A). Currently, no approved therapy is available for CMT1A patients. A novel…
View article: P1‐061: DOUBLE‐BLIND ARGUMENT FOR A SYNERGISTIC THERAPEUTIC EFFECT OF A FIXED LOW‐DOSE COMBINATION OF ACAMPROSATE AND BACLOFEN IN ALZHEIMER'S DISEASE
P1‐061: DOUBLE‐BLIND ARGUMENT FOR A SYNERGISTIC THERAPEUTIC EFFECT OF A FIXED LOW‐DOSE COMBINATION OF ACAMPROSATE AND BACLOFEN IN ALZHEIMER'S DISEASE Open
PXT-864, a fixed low-dose combination of repositioned acamprosate and baclofen, has shown multiple reversions of pathological alteration in cellular and animal models of Alzheimer's disease (AD) (Chumakov 2014), in addition of good safety …
View article: Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder
Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder Open
Charcot-Marie-Tooth disease type 1A (CMT1A), the most common form of Charcot-Marie-Tooth diseases, is a demyelinating neuropathy caused by a deletion encompassing the gene coding for PMP22, a myelin protein of the peripheral nervous system…
View article: [P3–047]: A COMBINATION OF ACAMPROSATE AND BACLOFEN (PXT864) SYNERGIZES WITH STANDARDS OF CARE FOR THE TREATMENT OF ALZHEIMER's DISEASE
[P3–047]: A COMBINATION OF ACAMPROSATE AND BACLOFEN (PXT864) SYNERGIZES WITH STANDARDS OF CARE FOR THE TREATMENT OF ALZHEIMER's DISEASE Open
Enhancing the efficacy of drugs targeting cognitive decline in Alzheimer disease (AD), together with improving their safety, has been a long-term goal of therapeutic development. Currently approved standards of care (SOCs) exhibit transien…
View article: Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A Open
View article: Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson’s disease
Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson’s disease Open
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterised by the loss of dopaminergic nigrostriatal neurons but which involves the loss of additional neurotransmitter pathways. Mono- or polytherapeutic intervention…
View article: Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy Open